Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2015-10-27 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Presentation of the third quarter 2015 results
Report Publication Announcement Classification · 95% confidence The document explicitly states it is a 'Presentation of the third quarter 2015 results' and details the time, location, and participants for the presentation and subsequent audio webcast/conference call. This content is characteristic of an Investor Presentation (IP) or materials related to an earnings event. Since it is announcing the presentation of results (which would typically be covered in an ER or CT), and the document itself is the announcement/invitation for the presentation, it fits best under Investor Presentation (IP) as it is the material being presented to investors, or potentially Report Publication Announcement (RPA) if it were just announcing the release of the formal report. However, given the focus on the presentation event itself (time, location, Q&A format implied by conference call), IP is a strong fit. If the document were the actual transcript, it would be CT. If it were just the key numbers, it would be ER. Since it is the announcement/details of the presentation event for the quarterly results, IP is the most appropriate classification for the presentation material itself, or RPA if it's just announcing the availability of the presentation slides/webcast. Given the context of providing details for the presentation event, I will classify it as Investor Presentation (IP), as the presentation slides are the core deliverable being discussed, even though the text is an announcement of that event. However, looking closely at the definitions, this document is announcing *when* and *how* the results presentation will happen, not providing the results themselves (ER) or the transcript (CT). It is announcing the event where the presentation will occur. This aligns closely with Report Publication Announcement (RPA) which covers announcements regarding the timing/release of company reports/presentations. Given the short length and focus on logistics, RPA is a safer classification than IP (which usually contains the slides themselves).
2015-10-27 English
Photocure: First patient enrolled in Hexvix®/Cysview® Phase 3 Market Expansion Study
Regulatory Filings Classification · 99% confidence The document is a press release from Photocure announcing a specific operational milestone: the enrollment of the first patient in a Phase 3 clinical study for Hexvix®/Cysview®. It contains company updates, quotes from management and a key physician, and details about the trial. This type of announcement, which is not a formal regulatory filing like a 10-K, a detailed financial report (IR), or a proxy statement, typically falls under general corporate news or investor relations updates. Since it is a specific announcement about clinical progress and market expansion, it is best classified as a general Regulatory Filing (RNS) as it is a formal disclosure to the market, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format, RNS is the most appropriate general disclosure category for non-standard, material news that isn't explicitly covered by other codes like ER or CAP. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR). Given the options, RNS serves as the best fit for a material, non-financial, non-governance press release.
2015-10-02 English
Photocure announces grant of new European patent for Cevira®
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure announcing the grant of a new European patent for its product Cevira®. It details the patent's scope, expiration date, and strategic importance. This type of announcement, which is a specific corporate update regarding intellectual property and product development, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a general corporate announcement. Since it is not a Director's Dealing (DIRS), a Financing Update (CAP), or a Legal Proceeding Report (LTR), the most appropriate fallback category for a specific, non-standard corporate update that is not a formal regulatory filing like an 8-K or equivalent, is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2015-09-22 English
Photocure ASA: Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Share capital increase registered' and details the number of new shares issued following the exercise of employee share options. It concludes by stating the new total registered share capital. This directly relates to a change in the company's capital structure via new share issuance, matching the definition for 'Share Issue/Capital Change' (SHA). It is not a general announcement of a report (RPA/RNS) because it contains the substantive information about the capital change itself, despite the short length.
2015-09-16 English
Photocure ASA: Resolved share capital increase in connection with exercise of options
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that the board of directors resolved a 'share capital increase' due to employees exercising options, resulting in the issuance of 50,830 new shares. This directly relates to a change in the company's capital structure through the issuance of new stock. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general announcement of a report (RPA/RNS) as it contains the substantive details of the capital change itself.
2015-09-08 English
Photocure announces submission of application for Hexvix® marketing authorization in Australia
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA announcing that its partner, Juno Pharmaceuticals, has filed a Marketing Authorization Application (MAA) for Hexvix in Australia with the Therapeutics Goods Agency. This is a specific corporate update regarding regulatory progress and partnership activities, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a general dividend/insider trade announcement. It details a specific business development event. Since there is no specific category for 'Regulatory Submission Announcement' or 'Partnership Update,' and it is a formal announcement of a corporate event, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory/corporate news that doesn't fit the highly specific financial report codes. Given the short length and announcement nature, it is not the full report itself.
2015-09-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.